The mutational profiling of primary and metastatic sites of cancer patients participating in early phase therapeutic trials provide an opportunity to identify distinct TP53 mutations that drive unique signaling pathways, which should guide rational drug combinations to abrogate oncogene addiction and drug resistance, hopefully with minimal toxicity to normal tissue. The gene discussed is TP53; the disease is cancer.